Trial results for tofacitinib in primary Sjogren's Syndrome were posted on ClinicalTrials.gov on 2025-12-18. The study, NCT04496960, evaluated the safety and tolerance of the oral Janus kinase inhibitor. Initial findings indicate a higher count of adverse events in the tofacitinib group compared to placebo across several categories.
Background
Tofacitinib is an oral Janus kinase inhibitor. Sjogren's syndrome is an autoimmune disease where the immune system attacks the body, often affecting multiple systems and organs. Researchers are investigating new treatments for this condition.
Trial design
The trial, NCT04496960, was a Phase 1/Phase 2 study designed to evaluate the safety and tolerance of tofacitinib in people with Sjogren's Syndrome. The study enrolled 23 participants aged 18-75 with Sjogren's Syndrome. Participants underwent medical and dental history, physical exams, medicine reviews, and electrocardiograms. The study compared adverse events between the tofacitinib group and a placebo group.
Key results
The trial's key measurements focused on the number of adverse events by grade or category. The recorded counts for adverse events were as follows:
- In one category, the tofacitinib group reported 19 adverse events, compared to 3 in the placebo group.
- In another category, the tofacitinib group reported 10 adverse events, compared to 7 in the placebo group.
- A further category showed 4 adverse events for tofacitinib versus 2 for placebo.
- Two categories reported 0 adverse events for both the tofacitinib and placebo groups.
- Finally, another category showed 4 adverse events for tofacitinib versus 1 for placebo.
All counts are in units of 'Count of adverse events'.
What this means
The results from this Phase 1/Phase 2 study indicate that tofacitinib was associated with a higher number of adverse events across several categories compared to placebo in participants with Sjogren's Syndrome. These findings are important for understanding the safety profile of tofacitinib in this patient population and will inform future research into its use for Sjogren's Syndrome.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04496960, titled "Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome," were posted on 2025-12-18 on clinicaltrials.gov.